Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 348 entries
View as:

Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01540539 Org: User:
Start: 03/31/12 End: 01/31/13 Due: 01/31/14

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Phase: N/A Priority: Normal
NCT ID: NCT02647086 Org: User:
Start: 12/31/15 End: 07/31/16 Due: 07/31/17

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

Phase: N/A Priority: Normal
NCT ID: NCT05791695 Org: User:
Start: 09/16/22 End: 09/15/23 Due: 09/15/24

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Phase: N/A Priority: Normal
NCT ID: NCT03633617 Org: User:
Start: 09/24/18 End: 06/07/22 Due: 06/07/23

Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

Phase: N/A Priority: Normal
NCT ID: NCT05906706 Org: User:
Start: - End: - Due: -

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Phase: N/A Priority: Normal
NCT ID: NCT01926782 Org: User:
Start: 09/30/13 End: 04/30/15 Due: 04/30/16

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

Phase: N/A Priority: Normal
NCT ID: NCT06593600 Org: User:
Start: 11/13/24 End: 04/21/26 Due: 04/21/27

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02290951 Org: User:
Start: 01/09/15 End: 09/30/25 Due: 09/30/26

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Phase: N/A Priority: Normal
NCT ID: NCT05394116 Org: User:
Start: 11/21/22 End: 02/27/29 Due: 02/27/30

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

Phase: N/A Priority: Normal
NCT ID: NCT06602739 Org: User:
Start: 11/19/24 End: 07/28/25 Due: 07/28/26

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03736967 Org: User:
Start: 11/12/18 End: 07/28/20 Due: 07/28/21

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03132636 Org: User:
Start: 06/29/17 End: 04/27/23 Due: 04/27/24

Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03084640 Org: User:
Start: 05/04/17 End: 09/30/21 Due: 09/30/22

Registry of Asthma Patients Initiating DUPIXENT®

Phase: N/A Priority: Normal
NCT ID: NCT04287621 Org: User:
Start: 03/02/20 End: 05/13/26 Due: 05/13/27

A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05505448 Org: User:
Start: 09/15/22 End: 05/30/23 Due: 05/30/24

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02680184 Org: User:
Start: 04/12/16 End: 12/06/22 Due: 12/06/23

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03515629 Org: User:
Start: 07/02/18 End: 07/29/21 Due: 07/29/22

A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations

Phase: N/A Priority: Normal
NCT ID: NCT05788536 Org: User:
Start: 05/12/23 End: 04/19/31 Due: 04/19/32

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Phase: N/A Priority: Normal
NCT ID: NCT01803321 Org: User:
Start: 11/30/05 End: 06/30/08 Due: 06/30/09

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Phase: N/A Priority: Normal
NCT ID: NCT03161093 Org: User:
Start: 08/17/17 End: 08/27/21 Due: 08/27/22

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

Phase: N/A Priority: Normal
NCT ID: NCT06548100 Org: User:
Start: 12/16/24 End: 06/28/27 Due: 06/28/28

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05618808 Org: User:
Start: 05/24/23 End: 05/27/24 Due: 05/27/25

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06454630 Org: User:
Start: 06/27/24 End: 01/21/25 Due: 01/21/26

Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Phase: N/A Priority: Normal
NCT ID: NCT03838731 Org: User:
Start: 02/12/19 End: 04/06/20 Due: 04/06/21

Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01484600 Org: User:
Start: 12/31/11 End: 02/29/12 Due: 02/28/13